European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Renewed interest in immunotherapy in treating kidney cancer

Thu, 13 Nov 2014

There is a renewed interest from medical researchers to further investigate the efficacy of immunotherapy for treating kidney cancer following the improved understanding of basic cancer immunology, according to cancer experts during the EAU-ICUD Medical Treatment of Urological Malignancies meeting which opened today in Lisbon, Portugal.

“In recent years we have seen a renewed interest from researchers. There is a doubling of abstracts at major conferences from 2009 and 2012. And approximately 800 clinical trials in various phases are ongoing in breast, colon, head and neck, kidney, etc.” said Allan Pantuck (USA).

The day-long EAU-ICUD meeting, which preceded the 6th European Multidisciplinary Meeting on Urological Cancers (EMUC), aims to gather experts in urological cancers and collate their consensus on various medical strategies for kidney, prostate, testis, bladder and penile cancers.

Christian Stief (DE), who co-chaired the meeting with Profs. Christopher Evans (USA) and Karim Fizazi (FR), said the online publication of the consensus document is expected to be released at the EAU Congress in Madrid.

“The committees and groups composed of experts from various countries were hard at work, and we are grateful for their contributions. We are excited with the final outcome of this consensus work which covers main urological malignancies,” said Stief.

The first session tackled renal cell carcinoma covering first-line targeted therapy, second and third-line therapeutic options and the prospects in immunotherapy and other alternative approaches.

Pantuck gave an overview on immunotherapy and said the discovery of a new class of drugs and checkpoint inhibitors have given rise to the renewed interest on immunotherapy. He also mentioned the benefits of immunotherapy such as its systemic and highly specific effect on tumour cells and ability to adapt to antigenic changes over time.

Cora Sternberg (IT) discussed the committee’s recommendations and consensus on topics such as interleukin-2, interferon, cytokines plus targeted therapies, immune checkpoint inhibitors and therapeutic cancer vaccines.

Among the highlights mentioned by Sternberg were:

On Interleukin-2: High dose intravenous IL-2 is currently the only approved treatment for mRCC that offers the possibility of long-term remission but should be used as first-line treatment only in carefully selected patients.

On Interferon: A meta-analysis of four randomized, prospective clinical trials by the Cochrane collaboration reported a higher remission rate of 12.5% for the IFNalpha group, compared to 1.5% for the control group. IFN was associated with a significant survival benefit with a median OS improvement of 3.8 months.

On Cytokines Plus Targeted Therapies: IFN with Bevacizumab has yielded encouraging results and remains a first line treatment option for patients with mRCC.

On Monoclonal Antibody Therapy (mAbs): mAbs targeting RCC cell surface molecules have been developed for imaging and therapy purposes

On Therapeutic Cancer Vaccines: Many uncontrolled RCC vaccine trials with seemingly impressive early phase clinical outcome data appear less impressive with the knowledge that some patients with metastatic RCC can have stable disease for long periods despite not receiving systemic therapy , and that partial and complete spontaneous regressions can occur in this group.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer